Citest has released a new series of Drug of Abuse (DOA) detection products in July 2025, marking a significant advancement in efficient drug testing. These solutions, catering to multiple specimen types like breast milk, saliva and drinks, aim to address varied testing needs in maternal health, personal monitoring and crime prevention.

 The product lineup includes three key offerings. The Multi-Drug Rapid Test for breast milk uses competitive binding, lateral flow immunochromatographic assays to simultaneously detect drugs/metabolites, safeguarding infant health during breastfeeding. The THC Rapid Test for saliva is a user-friendly self-test. It’s a competitive binding assay detecting THC at 3.5 ng/mL, with GC/MS or LC/MS needed for result confirmation. The Drink Check Test targets GHB and Ketamine, with dual - testing or single-analyte options to curb drug-facilitated crimes.

These products boast notable strengths. They offer multiple specimen choices, ensuring flexibility. High accuracy is achieved through advanced immunochromatographic technologies. Operation is convenient, with easy-to-use formats for self-testing or professional use. Safety is prioritized, from specimen collection (easier and safer for breast milk, saliva, and drinks) to result reliability, protecting both users and vulnerable groups like breastfed infants.

In conclusion, Citest’s new DOA detection products set a new industry standard. By blending convenience, accuracy and safety, they provide practical solutions across personal health and safety scenarios. This launch reflects the company’s commitment to innovative, reliable drug- testing tools, meeting the evolving demands of diverse user groups and contributing to public health and safety efforts.